Literature DB >> 12473757

The association of incident dementia with mortality in PD.

G Levy1, M-X Tang, E D Louis, L J Côté, B Alfaro, H Mejia, Y Stern, K Marder.   

Abstract

OBJECTIVE: To evaluate the association of incident dementia with mortality in a cohort of patients with idiopathic PD who were nondemented at baseline evaluation, controlling for extrapyramidal sign (EPS) severity at each study visit.
BACKGROUND: The development of dementia has been associated with reduced survival in PD. Because EPS severity is associated with both dementia and mortality in PD, the association of dementia with mortality may be confounded by disease severity.
METHODS: A cohort of patients with PD was followed annually with neurologic and neuropsychological evaluations. The association of incident dementia and the total Unified PD Rating Scale (UPDRS) motor score with mortality in PD was examined using Cox proportional hazards models with time-dependent covariates. All analyses were adjusted for age at baseline, sex, years of education, ethnicity, and duration of PD.
RESULTS: Of 180 PD patients, 41 (22.8%) died during a mean follow-up period of 3.9 +/- 2.2 years. Among those who died during the study period, 48.8% (20 of 41) became demented during follow-up, as compared to 23.0% (32 of 139) of those who remained alive. Both incident dementia (RR: 2.2, 95% CI: 1.1 to 4.5, p = 0.04) and the total UPDRS motor score at each study visit (RR: 1.04, 95% CI: 1.02 to 1.07, p = 0.001) were associated with mortality in PD when included in the same Cox model.
CONCLUSIONS: Incident dementia has an independent effect on mortality when controlling for EPS severity. The development of dementia is associated with a twofold increased mortality risk in PD.

Entities:  

Mesh:

Year:  2002        PMID: 12473757     DOI: 10.1212/01.wnl.0000036610.36834.e0

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  81 in total

1.  Quantitative EEG as a predictive biomarker for Parkinson disease dementia.

Authors:  B T Klassen; J G Hentz; H A Shill; E Driver-Dunckley; V G H Evidente; M N Sabbagh; C H Adler; J N Caviness
Journal:  Neurology       Date:  2011-06-01       Impact factor: 9.910

Review 2.  Mild cognitive impairment in Parkinson's disease.

Authors:  J G Goldman; I Litvan
Journal:  Minerva Med       Date:  2011-12       Impact factor: 4.806

Review 3.  Profile of cognitive impairment in Parkinson's disease.

Authors:  G Stennis Watson; James B Leverenz
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

4.  GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease.

Authors:  Ignacio F Mata; James B Leverenz; Daniel Weintraub; John Q Trojanowski; Alice Chen-Plotkin; Vivianna M Van Deerlin; Beate Ritz; Rebecca Rausch; Stewart A Factor; Cathy Wood-Siverio; Joseph F Quinn; Kathryn A Chung; Amie L Peterson-Hiller; Jennifer G Goldman; Glenn T Stebbins; Bryan Bernard; Alberto J Espay; Fredy J Revilla; Johnna Devoto; Liana S Rosenthal; Ted M Dawson; Marilyn S Albert; Debby Tsuang; Haley Huston; Dora Yearout; Shu-Ching Hu; Brenna A Cholerton; Thomas J Montine; Karen L Edwards; Cyrus P Zabetian
Journal:  Mov Disord       Date:  2015-08-21       Impact factor: 10.338

5.  Neurocognitive and atrophic patterns in Parkinson's disease based on subjective memory complaints.

Authors:  Jin Yong Hong; Ji Eun Lee; Young H Sohn; Phil Hyu Lee
Journal:  J Neurol       Date:  2012-08       Impact factor: 4.849

6.  Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia.

Authors:  R Ceravolo; D Volterrani; D Frosini; S Bernardini; C Rossi; C Logi; G Manca; L Kiferle; G Mariani; L Murri; U Bonuccelli
Journal:  J Neural Transm (Vienna)       Date:  2006-06-14       Impact factor: 3.575

7.  Rivastigmine for dementia associated with Parkinson's disease.

Authors:  John Morgan; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2005-07       Impact factor: 5.081

8.  Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study.

Authors:  B Ravina; M Putt; A Siderowf; J T Farrar; M Gillespie; A Crawley; H H Fernandez; M M Trieschmann; S Reichwein; T Simuni
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-07       Impact factor: 10.154

Review 9.  Oxidative damage to macromolecules in human Parkinson disease and the rotenone model.

Authors:  Laurie H Sanders; J Timothy Greenamyre
Journal:  Free Radic Biol Med       Date:  2013-01-15       Impact factor: 7.376

Review 10.  Psychiatric aspects of Parkinson's disease--an update.

Authors:  Anette Schrag
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.